Cite
The efficacy and safety of targeted therapy plus fulvestrant in postmenopausal women with hormone-receptor positive advanced breast cancer: A meta-analysis of randomized-control trials
MLA
Shi Fang-fang, et al. “The Efficacy and Safety of Targeted Therapy plus Fulvestrant in Postmenopausal Women with Hormone-Receptor Positive Advanced Breast Cancer: A Meta-Analysis of Randomized-Control Trials.” PLOS ONE, vol. 13, Sept. 2018, p. e0204202. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....a0910e1301e96eb86e9f7de24e3fd2e9&authtype=sso&custid=ns315887.
APA
Shi Fang-fang, Chen Yan, Gu Xiaoyi, Gao Chanchan, & Su Xiangyu. (2018). The efficacy and safety of targeted therapy plus fulvestrant in postmenopausal women with hormone-receptor positive advanced breast cancer: A meta-analysis of randomized-control trials. PLOS ONE, 13, e0204202.
Chicago
Shi Fang-fang, Chen Yan, Gu Xiaoyi, Gao Chanchan, and Su Xiangyu. 2018. “The Efficacy and Safety of Targeted Therapy plus Fulvestrant in Postmenopausal Women with Hormone-Receptor Positive Advanced Breast Cancer: A Meta-Analysis of Randomized-Control Trials.” PLOS ONE 13 (September): e0204202. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....a0910e1301e96eb86e9f7de24e3fd2e9&authtype=sso&custid=ns315887.